First and Black: 'Boy Mom' Swin Cash hasn't had time to reflect on the barriers she’s crossed

Vincent Goodwill
·7 min read

The jokes flew from the players when Swin Cash came waddling through the New Orleans Pelicans practice facility, fully pregnant, but the respect was still evident for the highest-ranking Black woman in basketball operations.

“Yeah, my kick game is still nice,” Cash would often say to the players, referring to her collection of Nike basketball shoes. “Maternity clothes and kicks, you know, they go together.”

Normalizing that level of fashion is small potatoes compared to the doors Cash has been smashing through the last couple of years. Becoming vice president of basketball operations under David Griffin was the first endeavor, one of his first hires in June 2019.

Then with national TV cameras in the Pelicans war room watching on draft night last November, she nonchalantly stood up and soon after, her phone was buzzing.

“People from the league were texting me like, 'Oh my God, you’re pregnant in a war room like what is going on here,'” Cash told Yahoo Sports. “One of my old colleagues from TV had hit me and was like, that might be the first time that we've seen a pregnant woman in that position. I guess we’re just kind of breaking all kinds of records.”

Cash takes immense pride in being the first Black woman in such a position in basketball operations, recognizing the gravity while also still wanting to learn every aspect of basketball operations — even amidst a pandemic.

So she kept the pregnancy quiet for a bit, choosing to focus on the work before the Pelicans went into the Orlando bubble last summer.

“I didn't want it to be a thing where, you know, a lot of times people announce like they're pregnant and you become this kind of a show where they have to take care of you, and ‘Are you OK?’, and ‘We don't want to bother you,’” Cash said. “And so I just kept grinding and I love that fact that I can look back and be able to tell that story.”

WNBA player Swin Cash speaks on stage at the Thurgood Marshall College Fund 27th Annual Awards Gala at the Washington Hilton on November 16, 2015 in Washington, DC.
New Orleans Pelicans executive Swin Cash recently had her second child. (Paul Morigi/Getty Images for Thurgood Marshall College Fund)

Cash now has a 3-week-old boy to go along with a 3-year old son, jokingly calling herself a “Boy Mom” as a play to the late Kobe Bryant’s term “Girl Dad,” but she hasn’t had time to truly reflect on the barriers she’s crossed over the last couple years. Her connection with Griffin stemmed from their days at NBA TV in Atlanta when they would spend hours discussing the game and the players. Griffin saw her acumen and told Cash he wanted to hire her when he got back into leading basketball operations.

Cash actually thought he was bluffing until he followed up on his word, knowing she carries cachet with today’s players and possesses the temperament for team building.

Her own basketball credentials are second-to-none: three-time WNBA champion with the Detroit Shock, four-time All-Star and two-time USA Basketball gold medalist (2004, 2012).

Diversity in NBA front offices has been a mixed bag through the years, better than the NFL but not nearly where the league wants it. Being a Black woman in a white man’s world, succeeding in it and commanding respect makes Cash a unicorn of sorts.

Even the stigma for being a former player, as the criteria for what front offices routinely look for, she’s had to battle.

But Cash has excelled in every facet of her basketball life, a quality analyst to the point where nobody bats an eye now when seeing WNBA great Candace Parker on NBA studio shows for TNT.

“I’ve just been about doing it, to be honest, because I'm in it,” Cash said. “And I feel like at some point I am going to have to breathe in. And the thing that's probably going to be after our season.”

It’s been full-speed ahead, even as Cash was preparing for the ultimate slowdown: delegating responsibilities to her teammates in the front office so they could survive without her.

Women in the workforce deal with that struggle through all walks and often return to settings that have moved on from them. Not that she needed permission, but Cash has found nothing but support and enthusiasm from Griffin and her co-workers.

“I've heard some horror stories, and I'm just really happy that that was never kind of my case,” Cash said. “One of the questions a lot of women asked was, ‘Do you take the whole maternity leave, do you feel it’ll lessen your value somewhat?’ You know, if you step away, like out of sight, out of mind.”

She credits Ramon Sessions, Adam Barnes and Alex Kaufman for helping in her stead, saying “It feels pretty good to know I have supportive colleagues, a great team and a progressive-minded staff and players to work with.”

“And we've been still pushing out and doing a lot of things that if I was still there would be getting done,” Cash said. “And so that's what it kind of makes me proud about this whole process is like, I guess less about me and more about like, Hey, this is how you effectively can continue to do your job.”

She knows she’s an example on a bunch of levels, especially in an unprecedented time. And there’s still an opportunity to create new norms.

“Be a mom like, yeah, it's not always easy, I’m not gonna say it’s peaches and cream,” Cash said. “But as I'm going back into this, what I feel like the first end of it, of preparing to step away, is done. Now I'm preparing to step back into it. And hopefully, that still would be in stride.”

The trade deadline is approaching, so perhaps she’ll be on calls with the Pelicans or with other teams while pumping — because infants eat on their own schedule regardless of what a team is doing.

Swin Cash speaks onstage during MTV's 2017 College Signing Day With Michelle Obama at The Public Theater on May 5, 2017 in New York City.
Swin Cash has no desire to ever become a coach in the NBA. (Mike Coppola/Getty Images for MTV)

She chuckles at the novelty of it all: Players have pregnant wives and girlfriends, family lives and circumstances that pull them away all the time.

“Don't just limit yourself,” Cash said. “If I want to have a family, I can't be a GM. I can't do this because it takes up too much time. Right? So I'm like, OK, so that it can take up too much of a dad's time, but it can't take too much of a mom. Make that make sense for me.” The seamless transition could very well be a model for front offices and coaching staffs around the league. If the most tumultuous circumstances can produce an adult-like adjustment, there’s no reason why it can’t happen when life returns to normal — or whatever normal looks like in a post-COVID society.

WNBA great Teresa Weatherspoon is an assistant on Stan Van Gundy’s staff, and more are sprinkled across the league. At some point, a franchise will make history and name a woman as head coach.

It won’t be Cash, though.

“Look, I wouldn't want to be a coach for anything in the world,” she joked. “I'd rather be in the front office. I wouldn't want to deal with them jokers every day.”

But there’s no glass ceiling above her, if things work out and she can lead a franchise as a team president or general manager, she wouldn’t run from it.

“I work with some great people,” Cash said. “And I told Griff and he's been great about it, too, is like, I want to learn all aspects of our business. If I aspire one day to kind of get there, great. If I don't, and I pivot in a different career at some point, that's fine, too.”

Just don’t tell the Boy Mom she can’t.

Latest Stories

  • Swimming's 'best kept secret' aiming for Tokyo heights

    "I like that title," says Abbie Wood. "Make sure to use that in your article."

  • Notice of annual general meeting 2021

    To Nasdaq OMX Copenhagen 02 March 2021 Company announcement no. 03/2021 Notice of annual general meeting 2021 The BANK of Greenland A/S will hold its annual general meeting on Wednesday 24 March 2021 at 4pm (WGT) at the BANK of Greenland’s head office in Nuuk. The agenda is included in the attached file. Contact: Anni Søe Svendsen, tel. +299 347802, mail: shareholder@banken.gl Attachment 03.Indkaldelse_2021_ENG

  • Brazil's Guedes says he will stay on as long as he has Bolsonaro's confidence

    Brazilian Economy Minister Paulo Guedes said on Tuesday he will stay in his post as long as he has the confidence of President Jair Bolsonaro. Guedes' relationship with Bolsonaro has come under scrutiny since the right-wing president pushed out the chief executive of state-run oil company Petrobras in February and threatened to interfere in other sectors of the economy. Speaking to Primocast, a podcast focused on financial matters, Guedes said he would not be swayed by external pressures.

  • Alarm grows in Serbia over virus surge; lockdown urged

    Serbian health experts urged the government on Tuesday to introduce a state of emergency and a strict lockdown to halt a surge in coronavirus infections that they say threaten the Balkan nation's health care system. Serbia has recorded nearly 4,500 virus-related deaths.

  • Q BioMed Awarded Federal Supply Contract for Strontium89 with U.S. Department of Defense and Veterans Affairs

    Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced today that it has signed an agreement for Strontium89 (Strontium Chloride Sr-89 Injection, USP) to be included on the Federal Supply Schedule ("FSS"). The agreement provides U.S. veterans and other federal government agencies access to Strontium89 for eligible patients. The final FSS contract is effective March 1, 2021 and has a five-year term. The FSS contract will extend access to Strontium89 to over nine million VA beneficiaries and others within the federal system.

  • Collection Sites Launches Operating Partnership To Extend COVID-19 Testing With Besser Brands; Medivolve Closes Noble Bioscience Transaction

    TORONTO, March 02, 2021 (GLOBE NEWSWIRE) -- Medivolve Inc. (“Medivolve” or the “Company”) (NEO:MEDV; OTC:COPRF; FRA:4NC) announces the launch of an operating model with Besser Brands in the state of Florida. Under this framework Besser Brands is initially operating 9 Collection Sites locations under the Collection Sites branding, where they are responsible for all related operating costs and systems management. In return for using the Collection Sites name, Besser Brands will pay a royalty on all tests sold. Further, Medivolve has entered into a definitive agreement and subsequently closed the transaction to acquire 100% of Noble Bioscience Corp. “We are excited by the opportunity to expand the Collection Sites network through an experienced and professional operating partner like Besser Brands,” says Doug Sommerville, CEO of Medivolve. “While we continue to operate our own network, implementing a franchise-type model will allow Collection Sites to more rapidly expand its network and leverage its infrastructure and branding to generate additional revenues for the company.” About Noble Bioscience Corp. Agreement Medivolve announced today that it has entered into a definitive agreement and subsequently closed the transaction to acquire 100% of Noble Bioscience Corp. (“Noble Bioscience”), first announced on February 2, 2021. Medivolve issued a total of 12.5 million Medivolve common shares to the shareholders of Noble Bioscience, in exchange for a 100% interest in Noble Bioscience. No finder fees were paid connection with, and no change of control of Medivolve resulted from, the transaction. Noble Bioscience holds the agency rights to Nuturell’s Surface Shield technology in the United States, Canada and Caribbean countries. Nuturell’s non-toxic silver surface shield technology is a COVID-19 disinfectant that converts into a protective shield when air dry, killing the coronavirus among other pathogens for up to 90 days after only ~30 seconds of contact. Nuturell’s Surface Shield technology was created to overcome the limitations of standard harsh chemical disinfectants and cleaning agents that suffer from various constraints such as their harmfulness, corrosive nature and bacterial resistance. Nuturell’s surface shield has a broad killing range of pathogens including the human coronavirus in only ~30 seconds of contact and is considered a “green” surface shield. Silver has been well-known as an antimicrobial agent and for its medicinal importance due to the remarkable pathogen killing properties. About Besser Brands Besser Brands was founded to seek projects and partnerships where their operational expertise and strategic capital can rapidly accelerate commercial value. Their management team has extensive experience in the personal health & well-being segment and the knowledge required to successfully navigate related regulatory frameworks in both the USA and Canada. About Collection Sites Collection Sites COVID-19 testing centers offer convenient access to rapid antibody and antigen tests - which take 8-10 minutes to administer and provide results in less than 24 hours. The sites also offer regular RT-PCR. All tests can be administered with insurance coverage options. The tests results can be communicated via text or email and can be accompanied with a certificate of good health via a HIPAA-compliant smartphone application. For more information about the pop-up labs, the available sites and services visit www.testbeforeyougo.com. About Medivolve Inc. Medivolve Inc. (NEO:MEDV; OTC:COPRF; FRA:4NC) seeks out disruptive technologies, ground-breaking innovations, and exclusive partnerships to help combat COVID-19 and generate remarkable risk-adjusted returns for investors. Specifically, Medivolve offers investors a diversified investment in the COVID-19 medical space across three areas; prevention, detection, and treatment. Medivolve has a team of renowned global medical and business advisors that have developed a proprietary business strategy to capitalize on high-margin opportunities in the COVID-19 space. This panel includes prominent immunologist Dr. Lawrence Steinman and Dr. Glenn Copeland, who has 45 years of experience in orthopaedic treatment, foot and ankle care, and sports medicine. Medivolve’s primary focus is to provide convenient and assessable medical services for testing of the COVID-19 virus to help combat the pandemic. This is achieved largely through two acquisitions: 100% of Collection Sites, LLC and 28% of Colombian Sanaty IPS. Collection Sites is setting up a series of COVID-19 testing sites across the United States with appointments and payments will be handled through the online portal www.testbeforeyougo.com. Sanaty is setting up a series of full-service medical clinics offering a complete COVID-19 testing solution. For additional information, please contact: Doug Sommerville, CEODoug.Sommerville@medivolve.ca For investing enquiries, please contact: info@medivolve.ca For US media enquiries, please contact: Veronica Welchveronica@vewprmedia.com Cautionary Note Regarding Forward-looking Information This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. Forward-looking information includes, but is not limited to, statements with respect to the closing of the Noble Bioscience transaction; the operating agreement with Besser Brands; the business and operations of the Company, and the Company’s ability to execute its business plan. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "expects" or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will be taken", "occur" or "be achieved". Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company, as the case may be, to be materially different from those expressed or implied by such forward-looking information. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. The Company does not undertake to update any forward-looking information, except in accordance with applicable securities laws. NEITHER NEO EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAS REVIEWED OR ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

  • CME Group Reports February 2021 Monthly Market Statistics

    CME Group, the world's leading and most diverse derivatives marketplace, today reported February 2021 market statistics, including average daily volume (ADV) of 24.6 million contracts during the month. Market statistics are available in greater detail at https://cmegroupinc.gcs-web.com/monthly-volume.

  • FTI Consulting Bolsters Power & Renewables Expertise

    Miriam Wrobel Joins as Senior Managing Director in San FranciscoWASHINGTON, March 02, 2021 (GLOBE NEWSWIRE) -- FTI Consulting, Inc. (NYSE: FCN) today announced the appointment of Miriam Wrobel as a Senior Managing Director in the Power & Renewables practice within the Corporate Finance & Restructuring segment at FTI Consulting, enhancing the firm’s clean energy strategic advisory offerings for clients throughout the deal lifecycle. Ms. Wrobel, who is based in San Francisco, is an expert in renewable energy strategy and finance, advising utilities, equity investors, lenders, project developers and large energy users on strategies for balancing risk and optimizing returns in energy transactions. At FTI Consulting, she will advise clients on energy transformation strategy, transaction structuring, diligence, ESG disclosure strategies and energy procurement. As energy markets evolve to be bi-directional and increasingly focused on integrating renewable and distributed resources, Ms. Wrobel will advise both large energy users as well as utilities, developers, owners and financiers of distributed and wholesale generation, storage and capacity. “Miriam expands our capability to provide utilities, power and renewable companies with reliable, well-informed and unbiased advice, guiding clients to economically and strategically valuable solutions,” said Chris LeWand, Global Power & Renewables Practice Leader at FTI Consulting. “Her counsel is grounded in a thorough understanding of each client’s goals, as well as deep knowledge of current trends, opportunities and players in the energy finance market. Miriam’s expertise will help clients navigate the evolving energy landscape, and we are fortunate to have someone of her caliber join our growing team.” Ms. Wrobel’s appointment comes as renewable energy deal flow starts to accelerate in 2021, underpinned by the Biden administration and a Democratic majority in Congress. According to FTI Consulting’s U.S. Renewables M&A: A Review of 2020 and Outlook for 2021, market activity likely will be influenced by the resulting certainty from tax credit extensions, as well as the Biden administration’s plan that provides for $2 trillion in investment across nine segments, including $400 billion in clean energy and innovation aimed at decarbonizing U.S. power generation by 2035. “Navigating the evolving energy markets requires deep industry knowledge and the ability to synthesize the capital market, as well as regulatory and operational implications of investment decisions,” Ms. Wrobel said. “By joining FTI Consulting and collaborating with experts across these disciplines, we can collectively provide unparalleled service to energy market participants on the West Coast and across the United States.” Prior to joining FTI Consulting, Ms. Wrobel was the President and Chief Executive Officer of Miriam Wrobel Consulting in San Francisco, where she provided strategic guidance on the financing of renewable, energy efficiency, storage, transportation and microgrid projects for utilities, investors and large energy users. Ms. Wrobel also has prior experience at Citigroup, where she was the primary relationship manager for renewable energy and energy efficiency developers within the Municipal Securities Division. She started her career in real estate with experience in the real estate acquisitions group at JPMorgan Asset Management and the investment research group at Lendlease Corp. About the FTI Consulting Power & Renewables PracticeCompanies involved in power generation face numerous hurdles, including low natural gas prices, slow growth in mature power generation markets, barriers to entry (both low and high), excess and idled plant capacity, reliance of renewable assets on supportive government policy incentives, global commoditization and economic natural gas alternatives, development of innovative technologies and entrance into new markets. Our global team delivers comprehensive services that address every need of companies involved in utility-scale generation, including nuclear, thermal, solar, wind and biomass, among other emerging low-carbon clean technologies, as well as energy storage. About FTI ConsultingFTI Consulting, Inc. is a global business advisory firm dedicated to helping organizations manage change, mitigate risk and resolve disputes: financial, legal, operational, political & regulatory, reputational and transactional. With more than 6,300 employees located in 28 countries, FTI Consulting professionals work closely with clients to anticipate, illuminate and overcome complex business challenges and make the most of opportunities. The Company generated $2.46 billion in revenues during fiscal year 2020. For more information, visit www.fticonsulting.com and connect with us on Twitter (@FTIConsulting), Facebook and LinkedIn. FTI Consulting, Inc. 555 12th Street NW Washington, DC 20004 +1.202.312.9100 Investor Contact: Mollie Hawkes+1.617.747.1791mollie.hawkes@fticonsulting.com Media Contact: Matthew Bashalany+1.617.897.1545matthew.bashalany@fticonsulting.com

  • Strongbridge Biopharma plc Announces Submission of New Drug Application for RECORLEV® (levoketoconazole) for the Treatment of Endogenous Cushing’s Syndrome to the U.S. Food & Drug Administration

    ~ RECORLEV® (levoketoconazole) New Drug Application is Supported by Previously-Reported Positive and Statistically Significant Results from the Phase 3 SONICS and LOGICS Studies ~ ~ Nearly 40 Percent of Prescription-Treated Endogenous Cushing’s Syndrome Patients in the U.S. Are Not Well-Controlled, Underscoring Need for New, Safe and Effective Pharmaceutical Options to Help Regulate Cortisol Levels ~ ~ If Approved Following a Projected 10-Month Review Cycle, RECORLEV is Anticipated to Launch in First Quarter of 2022 ~ DUBLIN, Ireland and TREVOSE, Pa., March 02, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that it submitted a New Drug Application (NDA) for RECORLEV® (levoketoconazole) for the treatment of endogenous Cushing’s syndrome to the U.S. Food and Drug Administration (FDA). The submission is supported by previously reported positive and statistically significant results of the SONICS and LOGICS trials: two Phase 3 multinational studies designed to evaluate the safety and efficacy of RECORLEV when used to treat adults with endogenous Cushing’s syndrome. “The submission of the New Drug Application for RECORLEV® (levoketoconazole) represents not only a significant milestone for Strongbridge but also for the Cushing’s syndrome community as a whole. As an organization focused on developing treatments for underserved rare disease patient populations, we are one step closer to helping address the needs of the estimated 8,000 Cushing’s syndrome patients in the U.S. who are treated with prescription therapy, many of whom, as we learned in our market research, are not well-controlled with current therapies,” said John H. Johnson, chief executive officer of Strongbridge Biopharma. “We look forward to working with the FDA through their review of our application, and we are actively preparing for the potential launch of RECORLEV in the first quarter of 2022, if approved.” RECORLEV, the pure 2S,4R enantiomer of the enantiomeric pair comprising ketoconazole, is a next-generation steroidogenesis inhibitor being investigated as a chronic therapy for adults with endogenous Cushing’s syndrome. Two Phase 3 studies have demonstrated substantial evidence of efficacy and safety in a combined study population of 166 patients that was representative of the adult drug-treated U.S. population with Cushing’s syndrome. The SONICS study met its primary and key secondary endpoints, demonstrating a statistically significant rate of mean urinary free cortisol normalization after six months of maintenance therapy without a dose increase (detailed results here). LOGICS, a double-blind, placebo-controlled randomized-withdrawal study, which also had statistically significant primary and key secondary endpoints, confirmed that the long-term cortisol-normalizing efficacy demonstrated in SONICS was due to use of levoketoconazole specifically (detailed results here). The long-term open-label extension study, OPTICS, is contributing safety information to the NDA. “We want to thank the patients, their families, investigators, collaborators, and employees who have contributed to the RECORLEV clinical program leading to this important regulatory milestone,” said Fredric Cohen, M.D., chief medical officer of Strongbridge Biopharma. RECORLEV has received orphan drug designation from the FDA and the European Medicines Agency for the treatment of endogenous Cushing's syndrome. Strongbridge will host a conference call tomorrow, Wednesday, March 3, 2021 at 8:30 a.m. ET to discuss the Company’s fourth quarter and full-year 2020 financial results and recent corporate highlights, including the RECORLEV NDA submission. About Cushing’s SyndromeEndogenous Cushing’s syndrome is a rare, serious and potentially lethal endocrine disease caused by chronic elevated cortisol exposure - often the result of a benign tumor of the pituitary gland. This benign tumor tells the body to overproduce high levels of cortisol for a sustained period of time, and this often results in undesirable physical changes. The disease is most common among adults between the ages of 30 to 50, and it affects women three times more often than men. Women with Cushing's syndrome may experience a variety of health issues including menstrual problems, difficulty becoming pregnant, excess male hormones (androgens), primarily testosterone which can cause hirsutism (growth of coarse body hair in a male pattern), oily skin, and acne. Additionally, the internal manifestations of the disease are potentially life threatening. These include metabolic changes such as high blood sugar, or diabetes, high blood pressure, high cholesterol, fragility of various tissues including blood vessels, skin, muscle and bone, and psychologic disturbances such as depression, anxiety and insomnia. Untreated, the five-year survival rate is only approximately 50 percent. About the SONICS StudySONICS is an open-label, Phase 3 study of RECORLEV as a treatment for endogenous Cushing’s syndrome that enrolled 94 patients at centers in North America, Europe and the Middle East. Following a screening phase, SONICS has three treatment phases: (1) Dose Titration Phase: Patients started RECORLEV at 150 mg twice daily (300 mg total daily dose) and titrated in 150 mg increments with the goal of achieving a therapeutic dose – a dose resulting in mUFC normalization – at which point titration was stopped; (2) Maintenance Phase: The dose was fixed and should not have been changed other than for safety reasons or loss of efficacy. At the end of the six-month maintenance phase, the mUFC response rate was measured; and (3) Extended Evaluation Phase: Patients continued on RECORLEV for another six months to evaluate long-term safety and tolerability and explore efficacy durability. About the LOGICS StudyThe Phase 3, multinational, double-blind, placebo-controlled, randomized-withdrawal study, LOGICS, randomized Cushing’s syndrome patients with baseline mean urinary free cortisol (mUFC) at least 1.5 times the upper limit of normal (ULN) following completion of a single-arm, open-label treatment phase of approximately 14 to 19 weeks, with RECORLEV individually titrated according to mUFC response. A total of 79 patients were dosed during the open-label titration-maintenance phase, 7 of whom had previously received RECORLEV during the SONICS study, and 72 who had not previously received RECORLEV. At study baseline, the median mUFC was 3.5 times the ULN, indicative of significant hypercortisolemia. A total of 44 patients (39 who had completed the titration-maintenance phase and five who directly enrolled from the SONICS study), were randomized to either continue RECORLEV (n=22) or to have treatment withdrawn by receiving a matching placebo regimen (n=22) for up to 8 weeks, followed by restoration to the prior regimen using blinded drug. Of the 44 patients randomized, 11 patients (25 percent) had previously received RECORLEV during the SONICS study. Patients who required rescue treatment with open-label RECORLEV during the randomized-withdrawal phase were considered to have lost mUFC response at the visit corresponding to their first dose of rescue medication. Patients who did not qualify for randomization were removed from open-label treatment prior to randomization and excused from the study. About RECORLEVRECORLEV® (levoketoconazole) is an investigational cortisol synthesis inhibitor in development for the treatment of patients with endogenous Cushing’s syndrome, a rare but serious and potentially lethal endocrine disease caused by chronic elevated cortisol exposure. RECORLEV is the pure 2S,4R enantiomer of ketoconazole, a steroidogenesis inhibitor. RECORLEV has demonstrated in two successful Phase 3 studies to significantly suppress serum cortisol and has the potential to be a next-generation cortisol inhibitor. The Phase 3 program for RECORLEV includes SONICS and LOGICS: two multinational studies designed to evaluate the safety and efficacy of RECORLEV when used to treat endogenous Cushing’s syndrome. The SONICS study met its primary and secondary endpoints, demonstrating a statistically significant normalization rate of urinary free cortisol at six months. The LOGICS study, which met its primary endpoint, is a double-blind, placebo-controlled randomized-withdrawal study of RECORLEV that is designed to supplement the long-term efficacy and safety information supplied by SONICS. The ongoing long-term open label OPTICS study will gather further useful information related to the long-term use of RECORLEV. RECORLEV has received orphan drug designation from the FDA and the European Medicines Agency for the treatment of endogenous Cushing's syndrome. About Strongbridge BiopharmaStrongbridge Biopharma is a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. Strongbridge’s rare endocrine franchise includes RECORLEV® (levoketoconazole), a cortisol synthesis inhibitor currently being studied in Phase 3 clinical studies for the treatment of endogenous Cushing’s syndrome, and veldoreotide extended release, a pre-clinical next-generation somatostatin analog being investigated for the treatment of acromegaly and potential additional applications in other conditions amenable to somatostatin receptor activation. Both RECORLEV and veldoreotide have received orphan drug designation from the FDA and the European Medicines Agency. The Company’s rare neuromuscular franchise includes KEVEYIS® (dichlorphenamide), the first and only FDA-approved treatment for hyperkalemic, hypokalemic, and related variants of primary periodic paralysis. KEVEYIS has orphan drug exclusivity in the United States. Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the federal securities laws. The words “anticipate,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “project,” “target,” “will,” “would,” or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. All statements, other than statements of historical facts, contained in this press release, are forward-looking statements, including statements related to data from the LOGICS and SONICS studies, the potential advantages of RECORLEV, the anticipated timing for potential approval of a marketing authorization for RECORLEV and for the potential launch of RECORLEV, Strongbridge’s strategy, plans, outcomes of product development efforts and objectives of management for future operations. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those expressed in such statement, including risks and uncertainties associated with clinical development and the regulatory approval process, the reproducibility of any reported results showing the benefits of RECORLEV, the adoption of RECORLEV by physicians, if approved, as treatment for any disease and the emergence of unexpected adverse events following regulatory approval and use of the product by patients. Additional risks and uncertainties relating to Strongbridge and its business can be found under the heading “Risk Factors” in Strongbridge’s Annual Report on Form 10-K for the year ended December 31, 2019 and its subsequent Quarterly Reports on Form 10-Q, as well as its other filings with the SEC. These forward-looking statements are based on current expectations, estimates, forecasts and projections and are not guarantees of future performance or development and involve known and unknown risks, uncertainties and other factors. The forward-looking statements contained in this press release are made as of the date of this press release, and Strongbridge Biopharma does not assume any obligation to update any forward-looking statements except as required by applicable law. Contacts: Corporate and Media RelationsElixir Health Public RelationsLindsay Rocco+1 862-596-1304lrocco@elixirhealthpr.com Investor RelationsSolebury TroutMike Biega+1 617-221-9660mbiega@soleburytrout.com

  • New real estate investment firm, Forest Gate, launches in Ontario

    The Board of Directors of Forest Gate Financial Corp. today announces the formation of Forest Gate, a new boutique private equity, private debt and real estate investment firm. To lead this new venture, the Board has appointed Daniel Marinovic as Chief Executive Officer and Managing Partner, and Frank DelZotto as Chief Financial Officer and Partner.

  • Australis Q3 2021 Conference Call

    Australis Capital Inc. (CSE: AUSA) (OTC: AUSAF) ("AUSA" or the "Company") is hosting a conference call today at 10:00pm ET to discuss its Q3 2021 financial results (see press release March 1, 2021) as well as the go forward business.

  • Monopar Partners with Seasoned Medtech Executive to Explore the Potential of MNPR-101 as a uPAR Imaging Agent in Cancer Surgery

    - Initial focus on use in bladder cancer surgeryWILMETTE, Ill., March 02, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced it has entered into an agreement with serial medtech entrepreneur, Andrew Cittadine, to explore over the next few months strategic and developmental options for MNPR-101 as an intraoperative imaging agent in bladder cancer surgery as well as other cancers. Mr. Cittadine is an experienced healthcare executive with a track record of building new businesses from concept through acquisition, including successful exits of Sensant Corp. to Siemens and American Biooptics to Olympus. Mr. Cittadine was the co-founder and Vice President of Marketing at Sensant Corp., and co-founder and CEO of American Biooptics. Sensant was an oncology imaging startup that developed 3D ultrasound imaging systems, and American Biooptics was a startup that developed an advanced oncology diagnostic test for gastrointestinal cancers. His most recent endeavors include serving as the CEO of Diagnostic Photonics, an imaging systems company for cancer surgeries. “It is a strong fit,” said Chandler Robinson, MD, Chief Executive Officer of Monopar, speaking to Mr. Cittadine’s expertise and the recent MNPR-101 bladder cancer imaging data published in a peer-reviewed article in the European Journal of Cancer. “Mr. Cittadine’s extensive experience in the oncology diagnostics and surgical imaging space combined with his previous successes makes for an ideal collaboration on exploring the potential of MNPR-101,” said Andrew Mazar, PhD, Chief Scientific Officer of Monopar. “The MNPR-101 based imaging agent has shown early promise in in vivo human bladder cancer models. I am excited to work with the Monopar team exploring ways to further the development of MNPR-101, be it through a spin-out, an out-licensing, a partnership, or developing it in-house,” said Andrew Cittadine, MBA. About Monopar Therapeutics Inc. Monopar Therapeutics is a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. Monopar's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients; camsirubicin for the treatment of advanced soft tissue sarcoma; and a late-stage preclinical antibody, MNPR-101, for advanced cancers and severe COVID-19. For more information, visit: www.monopartx.com. Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The forward-looking statements involve risks and uncertainties including, but not limited to the lack of any clinical activities to date with respect to MNPR-101 and that preclinical development activities to date have been focused on the treatment of cancers and not medical devices; the inability to successfully spin-out, out-license or develop a partnership, or if developed in-house, the requirement for additional capital to complete preclinical and clinical development of a medical device utilizing MNPR-101, and if successful, commercialization; if funding is available, not being able to develop MNPR-101 for use as a uPAR imaging agent in bladder cancer or any other indications; not being able to ensure volumes of MNPR-101 conjugates can be manufactured and scaled up to meet potential demand; uncertainties about levels of demand if and when a medical device is available for commercialization and the significant general risks and uncertainties surrounding the research, development, regulatory approval and commercialization of medical devices. Actual results may differ materially from those expressed or implied by such forward-looking statements. Risks are described more fully in Monopar's filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Monopar undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Any forward-looking statements contained in this press release represent Monopar’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. CONTACT: Monopar Therapeutics Inc: Investor Relations Kim R. Tsuchimoto Chief Financial Officer kimtsu@monopartx.com Follow Monopar on social media for updates: @MonoparTx Monopar Therapeutics

  • Neuronetics Reports Fourth Quarter and Full Year 2020 Financial and Operating Results

    MALVERN, Pa., March 02, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced its financial and operating results for the fourth quarter and full year of 2020. Fourth Quarter 2020 Highlights Fourth quarter 2020 revenue of $15.6 million, compared to $17.4 million in fourth quarter 2019, primarily due to the impact of the COVID-19 pandemicFourth quarter 2020 revenue increased $3.1 million, or 25%, compared to third quarter 2020Fourth quarter 2020 U.S. treatment session revenue of $11.0 million, compared to $11.2 million in fourth quarter 2019Fourth quarter 2020 U.S. NeuroStar® Advanced Therapy revenue of $3.6 million, compared to $5.4 million in fourth quarter 2019 Full Year 2020 Highlights Full year 2020 revenue of $49.2 millionFull year 2020 U.S. treatment session revenue of $34.9 millionFull year 2020 U.S. NeuroStar Advanced Therapy revenue of $11.1 million Recent Operational Highlights Added 18 new Business Development Managers and 10 new NeuroStar Practice Consultants as part of our sales organization optimization initiativeReceived FDA clearance for three-minute TouchStar® treatment protocol with our NeuroStar® Advanced Therapy SystemCompleted an offering of 5,566,000 shares of our common stock raising approximately $80.6 million in net cash in February 2021Amended our credit facility with Solar Capital Partners to reset revenue covenant requirements and to divide our $15.0 million Tranche B loan into three separate $5.0 million tranches Pro forma cash of approximately $130 million at the end of 2020 including the debt refinancing and equity refinancing “The fourth quarter was a strong finish to the year as we continued to see increased demand for NeuroStar Advanced Therapy systems as well as a rebound in the volume of patients undergoing treatment despite the continued uncertainty related to COVID-19,” said Keith J. Sullivan, President and Chief Executive Officer of Neuronetics. “We have done tremendous work in recent quarters to optimize our organization and build out a patient-focused commercial strategy. Looking ahead, we have a massive opportunity in front of us, and we will work diligently to bring the benefits of NeuroStar Advanced Therapy to all of the patients suffering from drug-resistant depression and other psychiatric disorders.” Fourth Quarter 2020 Financial and Operating Results Revenues by Geography Three Months ended December 31, 2020 2019 Amount Amount % Change (in thousands, except percentages) United States $15,046 $17,030 -12%International 533 326 63%Total revenues $15,579 $17,356 -10% Total revenue for the fourth quarter of 2020 was $15.6 million, a decrease of 10% over fourth quarter 2019 revenue of $17.4 million, primarily due to the impact of the COVID-19 pandemic and related governmental responses. During the quarter, total U.S. revenue declined by 12% and international revenue increased by 63% over the prior year quarter. Total revenue increased $3.1 million, or 25%, over the third quarter of 2020. United States Revenues by Product Category Three Months ended December 31, 2020 2019 Amount Amount % Change (in thousands, except percentages) NeuroStar Advanced Therapy System $3,620 $5,413 -33%Treatment sessions 11,029 11,243 -2%Other 397 374 6%Total United States revenues $15,046 $17,030 -12% United States NeuroStar Advanced Therapy System Revenues by Type Three Months ended December 31, 2020 2019 Amount Amount % Change (in thousands, except percentages) NeuroStar Capital $3,445 $4,959 -31%Operating lease 79 176 -55%Other 96 278 -65%Total U.S. NeuroStar Advanced Therapy System revenues $3,620 $5,413 -33% U.S. NeuroStar Advanced Therapy System revenue for the fourth quarter of 2020 was $3.6 million, a decrease of 33% over fourth quarter 2019 revenue of $5.4 million. The decrease was primarily driven by a lower number of NeuroStar systems sold in the quarter as many prospective customers had limited access to their offices in response to the COVID-19 pandemic. In the quarter, the Company sold 54 systems, down from 78 systems in the fourth quarter of 2019. U.S. NeuroStar Advanced Therapy System revenue increased by $1.1 million, or 42%, over the third quarter of 2020. As of December 31, 2020, the number of active sites was 916, up from 870 as of December 31, 2019. U.S. treatment session revenue for the fourth quarter of 2020 was $11.0 million, a decrease of 2% over revenue from the fourth quarter of 2019 of $11.2 million. The decrease was primarily driven by a reduction in per click treatment session volume because of COVID-19. In the fourth quarter, U.S. treatment session revenue per active site was $12,133 as compared to $13,497 during the fourth quarter of 2019. Gross margin for the fourth quarter of 2020 was 75.8%, consistent with the fourth quarter of 2019 gross margin of 75.7%. Operating expenses during the fourth quarter of 2020 were $14.5 million, a decrease of $5.6 million compared to $20.1 million in the fourth quarter of 2019. The decrease was primarily driven by our decrease in personnel costs related to our reduction in force undertaken in fiscal year 2020, as well as lower sales and marketing expenses driven by the impact of the COVID-19 pandemic. Net loss for the fourth quarter of 2020 was $(3.7) million, or $(0.19) per share, as compared to fourth quarter 2019 net loss of $(7.6) million, or $(0.41) per share. Net loss per share was based on 19,014,994 and 18,626,829 weighted-average common shares outstanding for the fourth quarters of 2020 and 2019, respectively. EBITDA for the fourth quarter of 2020 was $(2.4) million as compared to the fourth quarter of 2019 EBITDA of $(6.3) million. See the accompanying financial table that reconciles EBITDA, which is a non-GAAP financial measure, to net loss. Cash and cash equivalents were $49.0 million as of December 31, 2020. This compares to cash and cash equivalents of $50.7 million as of September 30, 2020 and $75.7 million as of December 31, 2019. Full Year Financial and Operating Results Revenues by Geography Year ended December 31, 2020 2019 Amount Amount % Change (in thousands, except percentages) United States $47,519 $60,760 -22%International 1,725 1,896 -9%Total revenues $49,244 $62,656 -21% Total revenues decreased by $13.4 million, or 21%, from $62.7 million for the year ended December 31, 2019 to $49.2 million for the year ended December 31, 2020, primarily due to the impact of the COVID-19 pandemic and related governmental responses. During the year, total U.S. revenue declined by 22% and international revenue declined by 9% over the prior year. United States Revenues by Product Category Year ended December 31, 2020 2019 Amount Amount % Change (in thousands, except percentages) NeuroStar Advanced Therapy System $11,094 $18,007 -38%Treatment sessions 34,852 41,120 -15%Other 1,573 1,633 -4%Total United States revenues $47,519 $60,760 -22% United States NeuroStar Advanced Therapy System Revenues by Type Year ended December 31, 2020 2019 Amount (in thousands, except percentages) NeuroStar Capital $10,518 $16,196 -35%Operating lease 437 730 -40%Other 139 1,081 -87%Total U.S. NeuroStar Advanced Therapy System revenues $11,094 $18,007 -38% U.S. NeuroStar Advanced Therapy System revenue decreased by $6.9 million, or 38%, in the year ended December 31, 2020 compared to the year ended December 31, 2019. The decrease was primarily driven by a lower number of NeuroStar systems sold during the year as many prospective customers had limited access to their offices in response to the COVID-19 pandemic. U.S. treatment session revenues decreased by 15% from $41.1 million for the year end December 31, 2019 to $34.9 million for the year ended December 31, 2020. The decrease was primarily driven by a reduction in per click treatment session volume during the quarter as a result of COVID-19. Gross margin for the full year 2020 was 76.5% compared to the full year 2019 gross margin of 75.4%. The slight increase in gross margin was the result of a higher mix of treatment session revenue. Operating expenses during the full year 2020 were $60.0 million, a decrease of $14.2 million, or 19%, compared to $74.2 million in the full year 2019. The decrease was primarily driven by the April reduction in workforce, a reduction in sales and marketing expense due to the impact of the COVID-19 pandemic, as well as lower research and development costs. Net loss for the full year 2020 was $(27.5) million, or $(1.46) per share, as compared to full year 2019 net loss of $(29.0) million, or $(1.58) per share. Net loss per share was based on 18,834,534 and 18,379,750 weighted-average common shares outstanding for the years ended 2020 and 2019, respectively. There were 19,114,132 shares outstanding as of December 31, 2020. EBITDA for the full year 2020 was $(22.0) million as compared to the full year 2019 EBITDA of $(24.3) million. The increase in EBITDA compared to the full year of 2019 is primarily due to the decrease in net loss for the same period. See the accompanying financial table that reconciles EBITDA, which is a non-GAAP financial measure, to net loss. Amendment of Solar Capital Credit Facility On December 8, 2020 we amended our term loan agreement with our current lenders and investment affiliates managed by Solar Capital Partners, LLC (“Solar”). The amendment includes the resetting of certain revenue covenants, and the dividing of the second tranche of the term loan (“Term B Loan”), originally $15.0 million, into three separate $5.0 million tranches. FDA Clearance for Three-Minute TouchStar Treatment Protocol On November 23, 2020, the U.S. Food and Drug Administration (“FDA”) granted clearance for our TouchStar treatment, a three-minute intermittent theta burst (iTBS) protocol with our NeuroStar Advanced Therapy System, administered with patented Contact Sensing technology. The new protocol arms physicians with the ability to now offer a third FDA-cleared treatment protocol with NeuroStar Advanced Therapy – a non-drug, non-invasive transcranial magnetic stimulation (“TMS”) treatment for Major Depressive Disorder (“MDD”) that uses magnetic pulses to stimulate areas of the brain that are underactive in depression. The three-minute TouchStar protocol allows clinicians to further customize treatments to best suit patient needs while increasing utilization of the NeuroStar Advanced Therapy System and expanding its benefits to more patients. Common Stock Offering On February 2, 2021, the Company closed an underwritten public offering of 5,566,000 shares of its common stock, including the exercise in full by the underwriters of their option to purchase up to an additional 726,000 shares of common stock, at a public offering price of $15.50 per share. Net proceeds from the offering were approximately $80.6 million. Business Outlook For the full year 2021, the Company expects to report total worldwide revenue between $58 million and $62 million. For the full year 2021, the Company expects operating expenses to be between $62 million and $66 million. For the first quarter of 2021, the Company expects to report total worldwide revenue of between $11 million and $12 million. Webcast and Conference Call Information Neuronetics’ management team will host a conference call on March 2, 2021 beginning at 8:30 a.m. Eastern Time. Investors interested in listening to the conference call on your telephone, please dial (877) 472-8990 for United States callers or +1 (629) 228-0778 for international callers and reference confirmation code 2124449, approximately ten minutes prior to start time. To access the live audio webcast or subsequent archived recording, visit the Investor Relations section of Neuronetics’ website at ir.neuronetics.com. The replay will be available on the Company's website for approximately 60 days. About Neuronetics Neuronetics, Inc. is a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Our first commercial product, the NeuroStar® Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The system is cleared by the United States Food and Drug Administration, or FDA, for the treatment of major depressive disorder in adult patients who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode. NeuroStar is also available in other parts of the world, including Japan, where it is listed under Japan’s national health insurance. Additional information can be found at www.neuronetics.com. “Safe harbor” statement under the Private Securities Litigation Reform Act of 1995: Statements in the press release regarding Neuronetics, Inc. (the “Company”) that are not historical facts constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may be identified by terms such as “outlook,” “potential,” “believe,” “expect,” “plan,” “anticipate,” “predict,” “may,” “will,” “could,” “would” and “should” as well as the negative of these terms and similar expressions. These statements include those relating to: the Company’s business outlook and current expectations for upcoming quarter and fiscal year 2021, including with respect to revenue, operating expense, growth, and any statements of assumptions underlying any of the foregoing items. These statements are subject to significant risks and uncertainties and actual results could differ materially from those projected. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this release. These risks and uncertainties include, without limitation, risks and uncertainties related to: the impact of COVID-19 on the Company’s operational and budget plans as well as general political and economic conditions, including as a result of efforts by governmental authorities to mitigate COVID-19, such as travel bans, shelter in place orders and third-party business closures and the related impact on resource allocations, manufacturing and supply chains and patient access to commercial products; the Company’s ability to execute its business continuity; the Company’s ability to achieve or sustain profitable operations due to its history of losses; the Company’s reliance on the sale and usage of its NeuroStar Advanced Therapy System to generate revenues; the scale and efficacy of the Company’s salesforce; availability of coverage and reimbursement from third-party payors for treatments using the Company’s products; physician and patient demand for treatments using the Company’s products; developments in respect of competing technologies and therapies for the indications that the Company’s products treat; product defects; the Company’s ability to obtain and maintain intellectual property protection for its technology; developments in clinical trials or regulatory review of NeuroStar Advanced Therapy System for additional indications; and developments in regulation in the United States and other applicable jurisdictions. For a discussion of these and other related risks, please refer to the Company’s recent SEC filings which are available on the SEC’s website at www.sec.gov. These forward-looking statements are based on the Company's expectations and assumptions as of the date of this press release. Except as required by law, the Company undertakes no duty or obligation to update any forward-looking statements contained in this press release as a result of new information, future events, or changes in the Company's expectations. Investor Contact: Mark R. KlausnerWestwicke Partners 443-213-0501ir@neuronetics.com Media Contact: Gina KentVault Communications610-455-2763gkent@vaultcommunications.com NEURONETICS, INC.Statements of Operations(Unaudited; In thousands, except per share data) Three Months ended Year ended December 31, December 31, 2020 2019 2020 2019 Revenues $15,579 $17,356 $49,244 $62,656 Cost of revenues 3,763 4,219 11,554 15,389 Gross Profit 11,816 13,137 37,690 47,267 Operating expenses: Sales and marketing 7,635 11,516 32,562 42,993 General and administrative 4,729 4,312 18,236 17,457 Research and development 2,112 4,248 9,201 13,747 Total operating expenses 14,476 20,076 59,999 74,197 Loss from Operations (2,660) (6,939) (22,309) (26,930)Other (income) expense: Interest expense 1,011 905 4,522 3,685 Loss on extinguishment of debt - - 924 - Other expense (income), net (14) (290) (302) (1,571)Net Loss $(3,657) $(7,554) $(27,453) $(29,044)Net loss per share of common stock outstanding, basic and diluted $(0.19) $(0.41) $(1.46) $(1.58)Weighted-average common shares outstanding, basic and diluted 19,015 18,627 18,835 18,380 NEURONETICS, INC.Balance Sheets(Unaudited; In thousands, except per share data) December 31,2020 December 31,2019 Assets Current assets: Cash and cash equivalents $48,957 $75,708 Accounts receivable, net 7,166 6,569 Inventory 3,720 2,775 Current portion of net investments in sales-type leases 1,887 880 Current portion of prepaid commission expense 1,096 689 Prepaid expenses and other current assets 2,186 1,830 Total current assets 65,012 88,451 Property and equipment, net 730 1,107 Operating lease right-of-use assets 3,418 3,796 Net investments in sales-type leases 2,331 1,730 Prepaid commission expense 5,300 3,779 Other assets 1,866 1,305 Total Assets $78,657 $100,168 Liabilities and Stockholders’ Equity Current liabilities: Accounts payable $3,749 $4,625 Accrued expenses 7,319 9,031 Deferred revenue 2,020 2,228 Current portion of operating lease liabilities 594 559 Current portion of long-term debt, net - 11,250 Total current liabilities 13,682 27,693 Long-term debt, net 34,620 19,898 Deferred revenue 1,741 2,106 Operating lease liabilities 3,121 2,619 Total Liabilities 53,164 52,316 Commitments and contingencies - - Stockholders’ Equity: Preferred stock, $0.01 par value: 10,000 shares authorized; no shares issued or outstanding at December 31, 2020 and 2019, respectively - - Common stock, $0.01 par value: 200,000 shares authorized; 19,114 and 18,645 shares issued and outstanding at December 31, 2020 and 2019, respectively 191 186 Additional paid-in capital 302,842 297,753 Accumulated deficit (277,540) (250,087)Total Stockholders' Equity 25,493 47,852 Total Liabilities and Stockholders’ Equity $78,657 $100,168 NEURONETICS, INC.Statements of Cash Flows(Unaudited; In thousands) Year ended December 31, 2020 2019 Cash Flows from Operating Activities: Net loss $(27,453) $(29,044)Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization 941 1,065 Share-based compensation 4,404 3,434 Non-cash interest expense 1,192 753 Cost of rental units purchased by customers 179 223 Loss on extinguishment of debt 622 - Changes in certain assets and liabilities: Accounts receivable, net (597) (950)Inventory (945) (306)Net investment in sales-type leases (1,609) (2,610)Leasehold reimbursement 836 - Prepaid commission expense (1,928) (4,468)Prepaid expenses and other assets (641) (565)Accounts payable (1,085) 299 Accrued expenses (1,733) 1,549 Deferred revenue (573) 138 Net Cash Used in Operating Activities (28,390) (30,482)Cash Flows from Investing Activities: Purchases of property and equipment and capitalized software (730) (813)Net Cash Used in Investing Activities (730) (813)Cash Flows from Financing Activities: Proceeds from issuance of long-term debt 41,360 - Repayment of long-term debt (38,860) - Payments of debt issuance costs (821) - Proceeds from exercises of stock options 690 2,420 Net Cash Provided by Financing Activities 2,369 2,420 Net (Decrease) Increase in Cash and Cash Equivalents (26,751) (28,875)Cash and Cash Equivalents, Beginning of Period 75,708 104,583 Cash and Cash Equivalents, End of Period $48,957 $75,708 Non-GAAP Financial Measures (Unaudited) EBITDA is not a measure of financial performance under generally accepted accounting principles in the United States, or GAAP, and should not be construed as a substitute for, or superior to, GAAP net loss. However, management uses both the GAAP and non-GAAP financial measures internally to evaluate and manage the Company’s operations and to better understand its business. Further, management believes the addition of the non-GAAP financial measure provides meaningful supplementary information to, and facilitates analysis by, investors in evaluating the Company’s financial performance, results of operations and trends. The Company’s calculation of EBITDA may not be comparable to similarly designated measures reported by other companies, because companies and investors may differ as to what type of events warrant adjustment. The following table reconciles reported net loss to EBITDA: Three Months ended Year ended December 31, December 31, 2020 2019 2020 2019 (in thousands) (in thousands) Net loss $(3,657) $(7,554) $(27,453) $(29,044) Interest expense 1,011 905 4,522 3,685 Income taxes - - - - Depreciation and amortization 200 300 941 1,065 EBITDA $(2,446) $(6,349) $(21,990) $(24,294)

  • AcuityAds Reports Fourth Quarter and Full Year 2020 Financial Results

    AcuityAds Holdings Inc. (TSX: AT) (OTCQX: ACUIF) ("AcuityAds" or "Company"), a technology leader that provides targeted digital media solutions enabling advertisers to connect intelligently with audiences across all digital advertising channels, today announced its financial results for the three and twelve months ended December 31, 2020.

  • Neurocrine Biosciences Announces Top-Line Results from Phase II INTERACT Study Evaluating Luvadaxistat (NBI-1065844) for the Treatment of Negative Symptoms and Cognitive Impairment Associated with Schizophrenia (CIAS)

    Neurocrine Biosciences (Nasdaq: NBIX) today announced that investigational drug luvadaxistat (NBI-1065844/TAK-831) did not meet its primary endpoint in the Phase II INTERACT study in adults with negative symptoms of schizophrenia, as measured by the change from baseline on the PANSS NSFS at Day 84. Luvadaxistat met secondary endpoints of cognitive assessment, which merit further clinical evaluation. The adverse event profiles for luvadaxistat were consistent with previous trials. Takeda Pharmaceutical Company Limited ("Takeda") granted an exclusive license to Neurocrine Biosciences for seven pipeline programs, including luvadaxistat, in June 2020. The results from the Phase II INTERACT study are being evaluated to determine next steps for development activities.

  • GBT Announces Participation at the H.C. Wainwright Global Life Sciences Conference

    SOUTH SAN FRANCISCO, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) will participate at the H.C. Wainwright Global Life Sciences Conference on Tuesday, March 9, 2021. A presentation by Ted W. Love, M.D., president and CEO of GBT, will be available at 7:00 a.m. ET. The presentation will be available on GBT’s website at www.gbt.com in the Investors section. A replay will be available for one month following the event. About Global Blood Therapeutics Global Blood Therapeutics (GBT) is a biopharmaceutical company dedicated to the discovery, development, and delivery of life-changing treatments that provide hope to underserved patient communities. Founded in 2011, GBT is delivering on its goal to transform the treatment and care of sickle cell disease (SCD), a lifelong, devastating inherited blood disorder. The company has introduced Oxbryta® (voxelotor) tablets, the first FDA-approved treatment that directly inhibits sickle hemoglobin polymerization, the root cause of red blood cell sickling in SCD. GBT is also advancing its pipeline program in SCD with inclacumab, a P-selectin inhibitor in development to address pain crises associated with the disease, and GBT021601 (GBT601), the company’s next generation hemoglobin S polymerization inhibitor. In addition, GBT’s drug discovery teams are working on new targets to develop the next wave of treatments for SCD. To learn more, please visit www.gbt.com and follow the company on Twitter @GBT_news. Contact:Steven Immergut (media)650.410.3258simmergut@gbt.com Courtney Roberts (investors)650.351.7881croberts@gbt.com

  • "Corona Virus Vaccine Market Size is Projected to reach 75.75 Billion by end of 2021, Says Brandessence Market Research"

    The Global Demand for global corona virus vaccine market in terms of revenue was worth of USD 0.37 Billion in 2020 and is expected to reach USD 75.75 Billion in 2021. The global corona virus vaccine market is expected to grow at significant growth rate due to number of driving factors.

  • APPlife Digital Solutions, Inc. Executes Definitive E-Commerce Platform License Agreement with Global Hemp Service LLC

    SAN FRANCISCO, March 02, 2021 (GLOBE NEWSWIRE) -- APPlife Digital Solutions, Inc. (OTCQB: ALDS) (“APPlife”, the Company”), a business incubator and portfolio manager that invests in and creates e-commerce and cloud-based solutions announced today that it has executed its previously announced letter of intent and signed a definitive agreement (“Agreement”) with Global Hemp Service LLC (“Global”). The Agreement provides Global with a perpetual, royalty-free, non-exclusive license to use APPlife’s market-ready and mobile website e-commerce platform to market, distribute, and sell its hemp, cannabidiol (“CBD”) and other related B2B and B2C products. As part of the Agreement, Global will pay APPlife a fee of 2.5% of its gross revenues, distributed on a quarterly basis. Additionally, APPlife will receive a total of 15% of the outstanding and fully diluted shares of Global. Global’s line of hemp and CBD products is expanding and will initially include fabrics, paper goods, hemp plastics, hemp building materials, hemp personal products (e.g., toilet paper, sanitary napkins, and tampons), hemp seed chicken feed, as well as high quality CBD oils and organic products for use in manufacturing. “We see this as a great opportunity to join a rapidly expanding market, as well as to participate in a space where the main objective is sustainability. Hemp and its derivatives are great for our environment, they use a fraction of the water to grow, purify the soil that it grows in, and can be replenished at an exponential rate compared to trees. Hemp plastics use no petroleum, and hemp building materials are fire retardant. The hemp seed is particularly rich in healthy fats, including omega-3 and omega-6 fatty acids and both fats are known for improving heart health by reducing cholesterol and blood pressure. The benefits and uses continue to be discovered, and APPlife is committed to positioning itself to participate in this growth,” stated Matt Reid CEO of APPlife. A recent report by market research company Grand View Research (“GVR”) predicts that the global industrial hemp market, currently estimated at USD$4.71 billion, will continue to grow throughout the next decade. GVR forecasts that the global hemp industry will register a compound average growth rate (“CAGR”) of 15.8% between 2020 and 2027 and will be driven by increased demand for hemp oil and fibers in the automotive, construction, food and beverage, personal care, and textile industries; especially in emerging regions such as the Asia Pacific. Concerning the global CBD market, which is currently valued at USD$2.8 billion, GVR expects a CAGR of 21.2% from 2021 to 2028, with revenues increasing from $9.3 billion in 2020 to $23.6 billion in 2028. Their analysis found that “due to its healing properties, the demand for CBD for health and wellness purposes is high, which is the major factor driving the market growth. In addition, the rising acceptance and use of products due to government approvals is a major factor expected to boost production for CBD-infused products.” ABOUT APPLIFE DIGITAL SOLUTIONS, INC.APPlife Digital Solutions Inc., with offices in San Francisco CA. and Shanghai China, is a business incubator and portfolio manager that uses digital technology to create and invests in e-commerce and cloud-based solutions. The Company invests in and creates solutions for work, home life, recreation and research that makes users more productive and more efficient, whether at work, home or traveling the world. APPlife's cloud-based businesses are designed to provide easy-to-use life solutions, often to address everyday issues and needs. They include a wide array of topics and needed services to cover the full marketplace across the spectrum. For more information visit www.applifedigital.com. Current APPlife Digital Solutions, Inc. e-commerce solutions: Rooster Essentials – The “Go To” eCommerce grooming shop for men. Bringing daily essentials to your doorstep. B2BCHX - Background check a Chinese company. Easy due diligence. Prevent fraud or scams. OfficeHop - A global sharing model platform for short term rentals of office and meeting rooms. (beta testing to begin end of 1st quarter 2021) Keep up to date on APPlife Digital Solutions events and developments join our online communities at Facebook, Twitter and LinkedIn. Contact Information:APPlife Digital SolutionsInvestor RelationsTel: (585) 232-5440Email: jody@applifedigital.com FORWARD-LOOKING STATEMENTS This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended, regarding, among other things our plans, strategies and prospects -- both business and financial. Although we believe that our plans, intentions, and expectations reflected in or suggested by these forward-looking statements are reasonable, we cannot assure you that we will achieve or realize these plans, acquisitions, intentions, or expectations. Forward-looking statements are inherently subject to risks, uncertainties, and assumptions. Many of the forward-looking statements contained in this news release may be identified by the use of forward-looking words such as "believe," "expect," "anticipate," "should," "planned," "will," "may," "intend," "estimated," and "potential," among others. Important factors that could cause actual results to differ materially from the forward-looking statements we make in this news release include market conditions and those set forth in reports or documents that we file from time to time with the United States Securities and Exchange Commission. All forward-looking statements attributable to APPlife Digital Solutions, Inc. or a person acting on its behalf are expressly qualified in their entirety by this cautionary language.

  • Microsoft announces early participation results of exchange offers

    Microsoft Corp. (NASDAQ: MSFT) ("Microsoft") today announced the early participation results of its offers to (i) exchange (the "Pool 1 Offer") the fourteen series of notes described in the table below (collectively, the "Pool 1 Notes") for a new series of Microsoft's notes due March 17, 2052 (the "New 2052 Notes") and a cash payment, as applicable:

  • Actinium Announces Participation in H.C. Wainwright Global Life Sciences Conference

    Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced that management will participate in the H.C. Wainwright (HCW) Global Life Sciences Conference, which is being held digitally March 9-10, 2021.